Topical Gene Therapy B-VEC Offers New Hope for Butterfly Skin Disease

A devastating genetic skin condition that has tormented patients for generations may finally have a meaningful weapon in its arsenal. Dystrophic epidermolysis bullosa, often described as one of the most painful rare diseases in medicine, causes skin to blister and tear at the slightest friction because the body cannot produce a structural protein that anchors the epidermis to the dermis. Now, a comprehensive review published in the Archives of Dermatological Research has synthesized the clinical evidence behind beremagene geperpavec-svdt, known as B-VEC and marketed as Vyjuvek, the first topical gene therapy ever approved by the US Food and Drug Administration. The review, conducted by researchers at Rutgers Robert Wood Johnson Medical School and collaborators in Australia, examined nineteen studies and identified four unique clinical trials, concluding that the therapy is both effective and well tolerated, while cautioning that larger and longer studies are still needed to define its ultimate place in treatment.

The biology underlying dystrophic epidermolysis bullosa explains why the disease is so relentless. In patients with the dystrophic form, mutations in the COL7A1 gene impair or abolish production of type VII collagen, the protein that forms anchoring fibrils, the tiny structures that fasten the basement membrane of the skin to the underlying connective tissue. Without these anchors, the skin layers separate under minimal mechanical stress, producing chronic open wounds, scarring, and, in severe recessive cases, fusion of fingers and toes, narrowing of the esophagus, and a markedly elevated lifetime risk of squamous cell carcinoma. Disease burden extends far beyond the skin, encompassing severe pain, malnutrition from oral blistering, enormous daily wound care routines, and healthcare costs that can reach hundreds of thousands of dollars per patient per year. Before gene-based approaches arrived, care was essentially supportive: meticulous bandaging, infection control, nutritional support, and pain management.

B-VEC represents a fundamentally different strategy. Rather than treating symptoms, it delivers a functional copy of the COL7A1 gene directly to wound sites, allowing the patient’s own skin cells to resume production of type VII collagen. The delivery vehicle is a modified herpes simplex virus type 1 vector, a choice that may surprise readers who associate herpesviruses with disease. In fact, HSV-1 has become one of the most attractive platforms for topical gene transfer because it is a large double-stranded DNA virus with a generous payload capacity, it naturally infects skin and mucosal cells, it can be manufactured to high titers, and, critically, it is a redosable vector. Earlier gene therapy platforms based on retroviruses or adeno-associated viruses often permitted only a single administration, but wounds in epidermolysis bullosa reopen repeatedly, so a therapy that can be applied week after week is a decisive practical advantage.

The pharmacology of the treatment reflects this redosing philosophy. B-VEC is applied topically as a gel to the wound bed, where the viral vector enters keratinocytes and fibroblasts and directs synthesis of type VII collagen. Because the vector is replication-deficient and confined to the treated surface, systemic exposure is minimal, and the pharmacokinetic profile is dominated by local delivery and clearance rather than distribution through the bloodstream. The pharmacodynamic effect is the reconstitution of anchoring fibrils at the dermal-epidermal junction, which restores mechanical stability to the skin and allows chronic wounds to close. The gel must be stored frozen and protected from light, and application is performed by trained caregivers or clinicians, typically on a weekly schedule, which has become the standard dosing rhythm in clinical practice.

The pivotal evidence comes from a phase I/II trial that enrolled patients with recessive dystrophic epidermolysis bullosa and treated pairs of comparable wounds within each patient, one with B-VEC and one with placebo, an intrapatient design that elegantly controls for individual differences in healing capacity. The results, published in Nature Medicine, showed a statistically significant difference in wound response based on responder analysis, with a P value of 0.0026. Wounds treated with the gene therapy achieved closure in a median of 13.5 days, with a 95 percent confidence interval of 8 to 21 days, compared with a median of 22.5 days for placebo-treated wounds, whose confidence interval stretched from 8 to 64 days. Biopsies from treated wounds confirmed the mechanistic story: type VII collagen deposition at the dermal-epidermal junction and evidence of newly formed anchoring fibrils, demonstrating that the delivered gene was not merely present but functionally active.

These early findings were confirmed in a phase III trial reported in the New England Journal of Medicine, again using the intrapatient design in which each patient served as their own control. At six months, complete wound closure was achieved in a significantly greater proportion of B-VEC-treated wounds, representing a 46 percent improvement over placebo, with a 95 percent confidence interval of 24 to 68 percent and a P value of 0.002. At three months the effect was even stronger, with a 51 percent improvement in complete wound closure, a confidence interval of 29 to 73 percent, and a P value below 0.001. The consistency of benefit across time points and across wound pairs within the same patients gave regulators and clinicians confidence that the effect was genuine rather than an artifact of patient selection. On the strength of this evidence, the FDA approved B-VEC in 2023 for patients aged six months and older with dystrophic epidermolysis bullosa, making it the first approved topical gene therapy of any kind and the first herpesvirus-based gene therapy in human medicine.

Approval, however, was not the end of the story. A subsequent open-label extension study followed patients for 112 weeks and revealed an important nuance: wound closure was not always permanent. Durability proved dependent on continued weekly dosing, meaning that when treatment stopped, previously closed wounds could reopen, consistent with the underlying genetic defect remaining uncorrected in the patient’s genome. This is a crucial conceptual distinction from gene therapies that permanently modify stem cells. B-VEC functions more like a chronic replacement therapy, supplying functional gene copies to the regenerating skin as long as treatment continues. Encouragingly, the extension study found no new safety concerns with prolonged administration, and adverse events remained consistent with those expected in this fragile patient population, such as wound-related complications and itching, with no evidence of vector-related toxicity or immune reactions that would limit continued use.

Evidence from outside the United States has strengthened the case for generalizability. An independent open-label trial conducted in Japanese patients reported efficacy and safety comparable to the American trials, an important finding for a therapy whose pivotal data came from a relatively small and ethnically narrow population. The review’s authors also place B-VEC in the broader therapeutic landscape now emerging for epidermolysis bullosa. Genetically corrected autologous epidermal grafts, in which a patient’s own keratinocytes are modified in the laboratory and transplanted back, have shown long-term benefit but require invasive procedures and specialized manufacturing. Prademagene zamikeracel, a cell-based gene therapy approved more recently, demonstrated positive phase III results. Oleogel-S10, a birch bark extract, offers a non-gene-based option for wound closure, and there is even a case report of ocular gene therapy being used to treat corneal involvement in a patient with dystrophic disease. Notably, no head-to-head comparator trials between these therapies exist, leaving clinicians to choose based on indirect comparisons.

The review is candid about the limitations of the evidence base. The pivotal trials involved small sample sizes, a nearly unavoidable constraint when studying an ultra-rare disease that affects only a small number of patients worldwide, and the intrapatient design, while scientifically elegant, does not address systemic outcomes such as overall wound burden, quality of life, or survival. Long-term risks, including the theoretical possibility of insertional mutagenesis or viral recombination, require continued surveillance as more patients accumulate years of exposure. The authors conclude that B-VEC is a promising but still evolving treatment option, and they call for longer-term, larger-scale, and comparative studies to fully define its role. For a disease in which patients and families have endured decades of palliative care with no disease-modifying options, the arrival of a weekly gel that helps wounds close by correcting the molecular defect at its source marks a genuine turning point, even as the field works to answer the questions that remain.

Subject of Research: Topical gene therapy with beremagene geperpavec for dystrophic epidermolysis bullosa

Article Title: Beremagene geperpavec (B-VEC): the first topical gene therapy for dystrophic epidermolysis bullosa

Article References: Wang, E., Dhillon, J., Sanabria, B., Pathak, G. N., Rao, B., & Murrell, D. F. (2026). Beremagene geperpavec (B-VEC): the first topical gene therapy for dystrophic epidermolysis bullosa. Archives of Dermatological Research, 318(1), Article 515. https://doi.org/10.1007/s00403-026-04864-5

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04864-5

Keywords: beremagene geperpavec, B-VEC, dystrophic epidermolysis bullosa, gene therapy, HSV-1 vector, collagen VII, wound healing, clinical trials, FDA approval, dermatology, rare disease, Vyjuvek